Generation of health and healthcare utilisation data, and work-related statistics from Precision Medicine intervention cohorts to generate evidence and demonstrate the value of Precision Medicine to stakeholders and inform policymaking

Precision Health Research, Singapore (PRECISE) is the central entity set up to coordinate a whole-of-government effort to implement Phase II of Singapore’s 10-year National Precision Medicine (NPM) strategy. As part of PRECISE’s vision to transform health in Singapore through Precision Medicine (PM), it has been working with its partners to develop and implement clinical pathways that integrate genetic testing. The eventual goal is to improve health outcomes for patients at a sustainable cost, while optimising for parameters that are important to funders and policy owners.

Various Clinical Implementation Pilots (CIPs) have been prioritised and funded as PM use cases because of their high potential to impact population health in Singapore. Given that there is a lengthy time horizon for the full benefits of PM to be realised (e.g. within decades or up to a lifetime), the TRUST platform provides a great opportunity to generate real-world aggregate local data to populate economic models to develop evidence and provide insight on the local implementation of these pilots. This would inform and guide policy decision-making for future at-scale implementation of PM in our local healthcare system to benefit Singapore and Singaporeans.